The Role of Neuromodulation in a Multimodal Approach to Migraine Treatment

Migraine is a multifaceted neurological disorder that often requires a personalized and comprehensive treatment strategy. Beyond the biological complexity of migraine pathophysiology, many patients face additional challenges, including limited access to specialized care, delays in diagnosis, and misaligned expectations about treatment outcomes. 

“With migraine freedom as a goal and, given the complex pathophysiology of migraine and the high incidence of comorbidities among individuals with migraine, treatment with a single modality may be insufficient, as it may not achieve migraine freedom in those with more frequent or disabling attacks,” concluded the authors of “Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review,” published in Neurology and Therapy.

While migraine freedom may seem aspirational for some patients, it is crucial to remain mindful of the profound individual, institutional, and societal burden of this disease. Migraine is among the leading causes of years lived with disability (YLDs) globally, and it is the top cause of YLDs in women aged 15 to 49. According to a study published in PRS Global, the inpatient cost burden of migraine rose dramatically from $176 million in 1997 to $1.2 billion by 2012. As the authors noted, “better prevention and improved outpatient treatment may help alleviate the inpatient burden of migraine.”

In this article, we examine the evolving role of neuromodulation as part of a multimodal and stratified treatment framework and how its integration may enhance outcomes in the management of migraine.

Why multimodal treatment is necessary for some migraine patients

There are compelling reasons why an individualized approach to migraine treatment is essential in modern clinical practice. Foremost, treatment efficacy varies widely between individuals. As Ihara et al. noted in a recent review, “Precision medicine is especially needed in the migraine field since the response to migraine treatments is not universal amongst all individuals with migraine.” This reflects the lived experience of many patients, who often find that therapies effective for others—including family or friends—may not work for them. A broad spectrum of treatment modalities, including lifestyle modifications, non-pharmacologic therapies, and pharmaceutical options, enables patients and clinicians to collaborate in developing a personalized, adaptable treatment plan aimed at optimizing outcomes.

Another key reason individualized approaches to migraine treatment are essential is the increasing complexity of medical comorbidities and the expanding array of pharmaceutical options. Many patients present with comorbid conditions—such as pregnancy or a history of stroke or myocardial infarction—that may serve as direct contraindications to specific migraine therapies, including anti-calcitonin gene-related peptide (CGRP) medications for pregnancy or triptans for cardiovascular or cerebrovascular disease. A recent article published in Nature Reviews Drug Discovery highlighted that the FDA approved 50 new pharmaceutical agents in 2024, marking it as the second-highest year for drug approvals in the past three decades, surpassed only by 2023, which saw 55 approvals. While the growing availability of therapeutic options is a positive development, it also raises concerns about polypharmacy and the potential for drug-drug interactions. These concerns further underscore the importance of a personalized, rather than one-size-fits-all, approach to migraine management.

Additional challenges to successful migraine management with monotherapy include:

• Access barriers, such as the high cost of newer medications, limited insurance coverage, and burdensome co-pays
  
• Risk of medication overuse headache, particularly when NSAIDs or triptans are used frequently for acute symptom relief
  
• Patient preferences, including a desire to pursue “drug-free” or non-pharmacologic treatment strategies
  
• Treatment intolerances, which are common with both pharmaceutical and non-pharmaceutical interventions, and may require alternative or adjunctive approaches

Four principles of multimodal migraine management

The authors of “Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review” propose that the selection of treatments in a multimodal approach should be governed by four key principles.

1. Manage common comorbid conditions. 

In the large, cross-sectional and longitudinal Chronic Migraine Epidemiology and Outcomes (CaMEO) Study, 92.4% of participants with migraine reported at least one comorbidity. Compared to people without migraine, migraine patients are three times more likely to have insomnia, depression, anxiety, and gastric ulcer or gastrointestinal bleeding, according to the Migraine in America Symptoms and Treatment (MAST) Study. Migraine patients are twice as likely to have peripheral artery disease, angina, allergies/hay fever, epilepsy, arthritis, rheumatoid arthritis, asthma, and vitamin deficiency. 

Effectively addressing common comorbidities such as mood disorders, sleep disturbances, cardiovascular risk factors, and gastrointestinal conditions not only enhances overall patient well-being but may also improve migraine outcomes and treatment responsiveness. Integrating comorbidity management into migraine care should be viewed as a standard component of personalized, high-quality migraine treatment.

2. Control modifiable risk factors for migraine progression.

Several modifiable risk factors play a significant role in the progression and chronification of migraine, particularly chronic migraine. These include chronic stress or inadequate stress management, sleep disturbances, medication overuse, obesity, untreated mood disorders such as depression and anxiety, dietary imbalances (e.g., skipped meals, dehydration), sedentary lifestyle, excessive intake of substances such as caffeine, alcohol, or recreational drugs, and environmental exposures like screen overuse or poor ergonomic posture. 

In a recent narrative review, the authors emphasized that medication overuse and excessive caffeine intake are among the most critical contributors to migraine chronification. Specifically, medications such as NSAIDs, ergots, opioids, barbiturates, and triptans are associated with the development of medication-overuse headache and can exacerbate the long-term burden of migraine.

3. Diagnose and treat secondary causes of headache.

Medication overuse headache is just one example. Other secondary headache disorders include headaches caused by head and/or neck trauma or injury; cranial and/or cervical vascular disorder; nonvascular intracranial disorder; a substance or withdrawal from a substance; infection; a disorder of homeostasis; a disorder of the cranium, neck, eyes, ears, nose, sinuses, teeth, mouth, or other facial or cervical structure; and psychiatric disorder. 

4. Individualize acute and preventive treatments to minimize pain, functional disability, and allodynia.  

It’s essential to understand the pathophysiology of migraine and how each particular acute or preventive treatment targets different physiological pathways. As the narrative review authors state, “The identification of peripheral and central pathways associated with migraine, including trigeminal, cortical, subcortical, and descending inhibitory pathways, provides diverse physiological targets for therapeutic intervention.” 

While clinical data is lacking, evidence suggests that certain migraine treatment combinations have an additive effect. “Combination treatments represent a rational and feasible approach that target multiple therapeutic pathways and could significantly improve patient outcomes, particularly for those with treatment-resistant migraine,” concluded the authors of “Combining treatments for migraine prophylaxis: the state-of-the-art,” a narrative review published in The Journal of Headache and Pain. 

An effective multimodal plan may include pharmacological interventions, behavioral interventions, and neuromodulatory devices.

How non-invasive neuromodulation devices fit into a multimodal migraine management plan 

Several non-invasive medical devices have been cleared by the FDA for preventation and acute treatment of migraine. These options include external trigeminal stimulation (eTNS), single-pulse transcranial magnetic stimulation (sTMS), noninvasive vagus nerve stimulation (nVNS), remote electrical neuromodulation (REN), and external concurrent occipital and trigeminal neurostimulation (eCOT-NS). 

All of these devices are non-invasive, have favorable safety profiles, and may be used alongside other treatments without the risk of drug-drug interaction, making them well-suited for integration into a patient’s migraine management plan. Specific clinical scenarios when neuromodulation should be considered include:

• A patient has contraindications to standard migraine medications (e.g., cardiovascular disease, pregnancy) or is at risk for drug-drug interactions.
• A patient demonstrates an incomplete or absent response to pharmacologic treatments
• A patient is unable to tolerate pharmaceutical treatments due to systemic side effects, drug-drug interactions or poor tolerability profiles.
• A patient expresses that they want to avoid pharmaceuticals or reduce overall medication intake due to personal preference or prior negative experiences.
• A patient has medication overuse headache (MOH), a common contributor to the chronification of migraine, and thus reducing acute medication reliance is critical.

The case for introducing neuromodulation early in the multimodal migraine management plan 

While neuromodulation is often reserved as a last-line intervention—typically considered only after multiple pharmaceutical options have failed—this perception is increasingly outdated. Given its favorable safety profile, low systemic burden, and growing evidence of efficacy in both the acute and preventive treatment of migraine, and versatility in use with or without pharmaceutical interventions, neuromodulation deserves consideration as a first- or second-line option, particularly for patients with contraindications to anti-migraine medications, intolerance to side effects, or preference for a non-pharmaceutical approach. Unlike traditional therapies that often target either prevention or acute management, neuromodulation uniquely addresses both dimensions through targeted modulation of migraine-relevant neural pathways.

This dual utility not only reduces the need for polypharmacy but also offers a personalized, mechanism-based alternative with minimal risk of systemic adverse effects or drug–drug interactions. As we continue to shift toward more individualized, multimodal care in migraine management, neuromodulation should be recognized not as a last resort, but as a proactive tool—capable of improving outcomes earlier in the treatment journey.